AVROBIO, which is developing stem cell gene therapies to cure rare lysosomal storage diseases, raised $100 million by offering 5.25 million shares at $19, above the proposed range. It had originally planned to raise $75 million by offering 4.4 million shares at a range of $16 to $18. Insiders had indicated on purchasing $37.5 million of the IPO.
AVROBIO plans to list on the Nasdaq under the symbol AVRO. Morgan Stanley, Cowen & Company and Wells Fargo Securities acted as lead managers on the deal.
